ABCA7 | ATP-binding cassette, sub-family A (ABC1), member 7 | Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Expressed in all |
ABCB11 | ATP-binding cassette, sub-family B (MDR/TAP), member 11 | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
ABCC11 | ATP-binding cassette, sub-family C (CFTR/MRP), member 11 | Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
ABCC2 | ATP-binding cassette, sub-family C (CFTR/MRP), member 2 | Cancer-related genes Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Group enriched |
ABCC3 | ATP-binding cassette, sub-family C (CFTR/MRP), member 3 | Cancer-related genes Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Mixed |
ABCC4 | ATP-binding cassette, sub-family C (CFTR/MRP), member 4 | Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
ADCY2 | Adenylate cyclase 2 (brain) | Enzymes Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
ADCY8 | Adenylate cyclase 8 (brain) | Enzymes Predicted intracellular proteins Predicted membrane proteins
| | | | | Group enriched |
ATP13A2 | ATPase type 13A2 | Disease related genes Plasma proteins Potential drug targets Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Expressed in all |
ATP1A3 | ATPase, Na+/K+ transporting, alpha 3 polypeptide | Disease related genes Enzymes Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
ATP2A1 | ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 | Disease related genes Enzymes Plasma proteins Potential drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enriched |
ATP2B1 | ATPase, Ca++ transporting, plasma membrane 1 | Enzymes Plasma proteins Predicted membrane proteins
| | | | | Expressed in all |
ATP2B2 | ATPase, Ca++ transporting, plasma membrane 2 | Enzymes Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
ATP2B3 | ATPase, Ca++ transporting, plasma membrane 3 | Cancer-related genes Disease related genes Enzymes Plasma proteins Potential drug targets Predicted membrane proteins
| | | | | Group enriched |
ATP2B4 | ATPase, Ca++ transporting, plasma membrane 4 | Enzymes Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Expressed in all |
ATP2C1 | ATPase, Ca++ transporting, type 2C, member 1 | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Expressed in all |
ATP4A | ATPase, H+/K+ exchanging, alpha polypeptide | Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enriched |
ATP8B1 | ATPase, aminophospholipid transporter, class I, type 8B, member 1 | Disease related genes Enzymes Potential drug targets Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Mixed |
CACNA1A | Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit | Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
CACNA1C | Calcium channel, voltage-dependent, L type, alpha 1C subunit | Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
CACNA1S | Calcium channel, voltage-dependent, L type, alpha 1S subunit | Disease related genes FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
CFTR | Cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
CLCN2 | Chloride channel, voltage-sensitive 2 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Mixed |
CLCN7 | Chloride channel, voltage-sensitive 7 | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Expressed in all |
HHATL | Hedgehog acyltransferase-like | Predicted membrane proteins
| | | | | Group enriched |
MFSD2B | Major facilitator superfamily domain containing 2B | Predicted membrane proteins
| | | | | Tissue enriched |
MT-CO1 | Mitochondrially encoded cytochrome c oxidase I | Disease related genes Enzymes Mitochondrial proteins Potential drug targets Predicted membrane proteins Transporters
| | | | | Expressed in all |
NNT | Nicotinamide nucleotide transhydrogenase | Disease related genes Enzymes Mitochondrial proteins Plasma proteins Potential drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
NPC1L1 | NPC1-like 1 | FDA approved drug targets Predicted membrane proteins
| | | | | Group enriched |
PIGN | Phosphatidylinositol glycan anchor biosynthesis, class N | Disease related genes Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
PKDREJ | Polycystin (PKD) family receptor for egg jelly | Predicted membrane proteins
| | | | | Tissue enriched |
RHCG | Rh family, C glycoprotein | Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SCN2A | Sodium channel, voltage-gated, type II, alpha subunit | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enriched |
SERINC5 | Serine incorporator 5 | Predicted membrane proteins
| | | | | Expressed in all |
SLC12A1 | Solute carrier family 12 (sodium/potassium/chloride transporter), member 1 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC12A3 | Solute carrier family 12 (sodium/chloride transporter), member 3 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC12A5 | Solute carrier family 12 (potassium/chloride transporter), member 5 | FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC13A2 | Solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 2 | Predicted membrane proteins Transporters
| | | | | Group enriched |
SLC13A3 | Solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 3 | Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC17A6 | Solute carrier family 17 (vesicular glutamate transporter), member 6 | Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC17A7 | Solute carrier family 17 (vesicular glutamate transporter), member 7 | Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC1A2 | Solute carrier family 1 (glial high affinity glutamate transporter), member 2 | Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC1A3 | Solute carrier family 1 (glial high affinity glutamate transporter), member 3 | Cancer-related genes Disease related genes Plasma proteins Potential drug targets Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC1A6 | Solute carrier family 1 (high affinity aspartate/glutamate transporter), member 6 | Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Group enriched |
SLC22A12 | Solute carrier family 22 (organic anion/urate transporter), member 12 | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC22A13 | Solute carrier family 22 (organic anion/urate transporter), member 13 | Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC22A15 | Solute carrier family 22, member 15 | Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
SLC22A2 | Solute carrier family 22 (organic cation transporter), member 2 | Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC22A8 | Solute carrier family 22 (organic anion transporter), member 8 | FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC23A1 | Solute carrier family 23 (ascorbic acid transporter), member 1 | Predicted membrane proteins Transporters
| | | | | Tissue enhanced |